Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
Serina Therapeutics announced the Safety Monitoring Committee's recommendation to proceed to Cohort 2 in its Phase 1b registrational study of SER-252 for advanced Parkinson's disease after favorable blinded safety, tolerability, and pharmacokinetic data from Cohort 1. Early exploratory clinical observations indicated sustained motor function improv…